The Latest Breaking News from FOLD

Still haven’t organised a solid New Year’s Eve Plan? Here’s a handpicked list of the best club nights to ring in 2025

Amid the growing innovations, emphasis on enhanced treatment alternatives, and rapid AI adoption, the biotechnology industry is poised for solid long-term growth. Thus, investors could consider adding high-growth biotech stocks MannKind (MNKD), Amicus Therapeutics (FOLD), and Esperion Therapeutics (ESPR) to their watchlist. Continue reading.

Healthcare is considered a reliable defensive sector. So, amid the current uncertain economic landscape, let's determine the more favorable investment option between two prominent pharmaceutical companies, Moderna (MRNA) and Amicus Therapeutics (FOLD). Keep reading.

The ever-rising demand for quality healthcare is expected to benefit the biotech industry. Moreover, favorable government initiatives to boost domestic biotech research and production should boost the industry’s prospects. Therefore, it could be wise to buy fundamentally strong biotech stocks Shionogi & Co. (SGIOY), Amicus Therapeutics (FOLD), and Entrada Therapeutics…

With the biotech industry experiencing significant growth due to the increasing demand for healthcare solutions, fundamentally sound stocks such as Amicus Therapeutics (FOLD), POINT Biopharma Global (PNT), and Precision BioSciences (DTIL) might have the potential to provide substantial returns for investors and could be valuable portfolio additions this month. Learn…

The biotech industry is well-positioned to witness significant growth due to technological advancements and government spending. Moreover, given the sector’s defensive nature, biotech stocks Amicus Therapeutics (FOLD), Corcept Therapeutics (CORT), and Harmony Biosciences (HRMY) might be solid buys in 2023. Read on.

The Pixel Fold is Google's first foray into the foldable space brings an incredibly slim design, beyond all-day battery life and Google's excellent camera at an eye-watering price.

Given the breakthrough developments and government initiatives, the biotech industry is well-positioned to grow steadily. Therefore, fundamentally strong biotech stocks Amicus Therapeutics (FOLD) and POINT Biopharma (PNT) could be worth buying now. Read on.

As the biotech sector is expanding rapidly in response to the growing need for healthcare solutions, fundamentally strong biotech stocks Amicus Therapeutics (FOLD), Ardelyx (ARDX), and Genfit S.A. (GNFT) have the potential to generate substantial returns for investors. Hence, these stocks could be solid watchlist additions this month. Read more….